Tessenderlo’s 15% Minority Stake in Upcoming Darling Collagen JV Offers Leveraged Entry Into High-Growth Protein Market

Tessenderlo's 2025 performance established a solid operational and financial foundation. The core business delivered robust growth, with adjusted EBITDA reaching €288.1 million. This figure reflects a 10.7% increase on an internal growth basis, driven by operational execution, but was partially offset by a foreign exchange headwind of €5.8 million. The underlying momentum is clear, with internal growth contributing €28.4 million to the top line.

Financially, the company demonstrated disciplined capital management. The net cash position improved significantly, moving from a slight net debt of €-41.3 million at year-end 2024 to a slight net debt of €-5.0 million at year-end 2025. This narrowing of the net debt position, despite strong operational cash generation, underscores a focus on balance sheet strength. The improvement was supported by a reduction in capital expenditure and a decline in cash flow from operating activities, which suggests the company prioritized deleveraging over reinvestment during the period.

Capital allocation to shareholders was a consistent theme throughout the year. The board maintained its commitment to returning capital, executing an active share repurchase program that saw the group acquire 1,492,496 treasury shares for a total value of €37.0 million. This program, finalized by year-end, provided a direct return to investors while also reducing the share count, a structural tailwind for earnings per share.

The bottom line is one of steady, quality growth underpinned by balance sheet prudence and a clear capital return policy. For institutional investors, this baseline provides a stable platform from which to assess the upcoming joint venture catalyst.

Strategic Portfolio Shift: The Darling Joint Venture and Capital Allocation

The December 2025 agreement to combine Tessenderlo's collagen and gelatin segments with Darling Ingredients represents a disciplined capital-light strategic pivot. Under the definitive terms, Darling will hold an 85% majority stake in the new joint venture, while Tessenderlo retains a 15% minority position. This structure is a textbook example of a quality factor play, allowing the group to participate in a high-growth specialty protein market without bearing the full investment and operational burden of a majority stake.

For institutional allocators, this move signals a shift from direct ownership to a more selective, risk-adjusted exposure. The strategic rationale is clear: Tessenderlo is monetizing a valuable but capital-intensive asset base by partnering with a global leader in the space. This allows the company to redeploy its balance sheet toward higher-return opportunities within its core agrochemical and fertilizer operations, as evidenced by recent targeted acquisitions in specialty fertilizers. The decision reflects a prioritization of capital allocation efficiency over scale.

The transaction is expected to close in 2026, pending regulatory approvals and other closing conditions. This timeline is critical for portfolio construction, as it will finalize the strategic shift and unlock the first tangible capital return from the venture. Until then, the 15% stake provides a leveraged, low-cost entry into a structural tailwind sector. For investors, the setup is one of enhanced portfolio flexibility-maintaining a quality earnings stream while positioning for a potential future capital event as the joint venture scales.

Valuation and Sector Positioning: Weighing the Core Against the Catalyst

The institutional case for Tessenderlo now hinges on a clear bifurcation. The market currently prices the company as a steady industrial conglomerate, with its core agrochemical and fertilizer operations providing reliable, albeit moderate, growth. The recent acquisition of a Swedish SOP plant and targeted fertilizer label purchases signal continued focus on this high-quality, cash-generative segment. This baseline offers a defensive quality factor, but its valuation likely reflects the maturity of these established businesses.

The potential for re-rating lies entirely in the upcoming joint venture with Darling Ingredients. The transaction, expected to close in 2026, represents a structural tailwind for the specialty proteins segment. By combining with Darling's Rousselot business, the new venture is positioned to capture growth in high-value collagen and gelatin markets. For Tessenderlo, this is a capital-light way to participate in that expansion, effectively unlocking hidden value tied to an asset it is not fully monetizing through direct ownership.

Yet this catalyst carries significant execution risk. The primary concern is the dilution of control: Tessenderlo will hold only a 15% minority stake in the combined entity. This structure means the group's earnings exposure is leveraged to the venture's success, but its influence over strategic direction is limited. The market's reaction to this asymmetric arrangement will be critical. A smooth integration and strong early performance from the joint venture could justify a re-rating, but any execution missteps or governance friction would likely be punished, given the concentrated risk.

For portfolio allocators, the primary catalyst is the 2026 closing. This event will determine the quality factor and risk premium of the new allocation. It will convert a strategic promise into a tangible, albeit minority, equity position in a growing specialty business. Until then, the investment is a bet on management's ability to execute a complex deal while maintaining the core's disciplined growth. The setup offers a blend of stability and potential upside, but the risk-adjusted return profile will only become clear once the joint venture is operational.

Catalysts, Risks, and Portfolio Watchpoints

The strategic pivot now enters its critical execution phase. The primary catalyst is the expected closing of the Darling joint venture in 2026, pending regulatory approvals and other closing conditions. This event will convert a strategic promise into a tangible, albeit minority, equity position in a growing specialty business. For institutional investors, the timeline is paramount; the closing will finalize the capital-light shift and unlock the first phase of value realization from the venture.

Key risks to monitor are concentrated around execution and market perception. Regulatory hurdles remain a potential delay, though the structure of a joint venture with a global partner like Darling may mitigate some of these. More significant is the risk of integration friction, as the success of the combined Rousselot and PB Leiner operations will hinge on seamless operational and cultural alignment. The market's valuation of Tessenderlo's 15% stake is the ultimate arbiter of success. Given the group's limited control, any underperformance or governance issues in the new entity could be punished, while strong early results could justify a re-rating of the core.

Institutional investors should watch for post-closing financial disclosures from the joint venture to assess its contribution to Tessenderlo's adjusted EBITDA and capital structure. The initial financials will provide the first concrete data on the venture's growth trajectory and profitability, allowing allocators to gauge the quality factor and risk premium of this new, leveraged exposure. Until then, the investment remains a bet on management's ability to execute a complex deal while maintaining the core's disciplined growth. The setup offers a blend of stability and potential upside, but the risk-adjusted return profile will only become clear once the joint venture is operational.